Precision Medicine in Neurodegenerative Disorders

Part 1 Conceptual Framework1. The definition of precision medicine in neurodegenerative disorders and the one disease-many-diseases tension2. Models of precision medicine for neurodegeneration3. Pathology vs pathogenesis: Rationale and pitfalls in the clinicopathology model of neurodegeneration4. Mixed pathology as a rule, not exception: Time to reconsider disease nosology?5. Neurodegenerative disorders: From clinicopathology convergence to systems biology divergence6. The emergence of genotypic divergence and future precision medicine applications7. Lessons from other fields of medicine, Part 1: Breast cancer8. Lessons from other fields of medicine, Part 2: Cystic fibrosis9. Lessons learned from evolving frameworks in adult glioblastoma Part 2 Pitfalls in Definitions, Cohorts, and Measures of Progression10. Finding the falsification threshold of the toxic proteinopathy hypothesis in neurodegeneration11. The theoretical problems of "prodrome and "phenoconversion in neurodegeneration12. The dilemma between milestones of progression vs. clinical scales in Parkinson disease13. Biomarkers of diagnosis, prognosis, pathogenesis, response to therapy: Convergence or divergence? Lessons from Alzheimer Disease and synucleinopathies14. Challenges in the study of individuals at risk for Parkinson disease15. The challenging quest of neuroimaging: From clinical to molecular-based subtyping of Parkinson disease and atypical parkinsonisms